Carladenise Armbrister Edwards Sells 200,000 Shares of Clover Health Investments, Corp. (NASDAQ:CLOV) Stock

Clover Health Investments, Corp. (NASDAQ:CLOV) Director Carladenise Armbrister Edwards sold 200,000 shares of Clover Health Investments stock in a transaction on Friday, March 7th. The shares were sold at an average price of $3.61, for a total transaction of $722,000.00. Following the completion of the sale, the director now directly owns 273,227 shares in the company, valued at $986,349.47. This represents a 42.26 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Clover Health Investments Stock Performance

NASDAQ CLOV opened at $3.61 on Thursday. The business has a fifty day moving average price of $4.10 and a 200 day moving average price of $3.62. The company has a market cap of $1.84 billion, a P/E ratio of -18.05 and a beta of 2.00. Clover Health Investments, Corp. has a one year low of $0.61 and a one year high of $4.87.

Institutional Investors Weigh In On Clover Health Investments

A number of hedge funds have recently modified their holdings of the business. Concurrent Investment Advisors LLC acquired a new position in Clover Health Investments during the third quarter worth about $28,000. Sigma Planning Corp purchased a new position in Clover Health Investments in the 3rd quarter worth approximately $29,000. Parallax Volatility Advisers L.P. acquired a new position in shares of Clover Health Investments during the 3rd quarter worth approximately $38,000. Triumph Capital Management purchased a new stake in shares of Clover Health Investments in the fourth quarter valued at approximately $45,000. Finally, KBC Group NV purchased a new stake in shares of Clover Health Investments in the third quarter valued at approximately $53,000. 19.77% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

CLOV has been the topic of several recent analyst reports. Canaccord Genuity Group increased their price objective on shares of Clover Health Investments from $4.20 to $4.50 and gave the company a “buy” rating in a report on Monday, March 3rd. Craig Hallum started coverage on shares of Clover Health Investments in a research note on Tuesday, December 17th. They issued a “buy” rating and a $6.00 price target on the stock.

About Clover Health Investments

Clover Health Investments, Corp. provides medicare advantage plans in the United States. It operates through two segments: Insurance and Non-Insurance. It also offers Clover Assistant, a cloud-based software platform, that enables physicians to detect, identify, and manage chronic diseases earlier; and access to data-driven and personalized insights for the patients they treat.